US EditionBiomimetic Nanotherapy Shows Promise for Treating Fatal Lung Scarring Disease
- On June 20, 2025, a team led by scientists from Yale School of Medicine, together with international partners, published a study using artificial intelligence to advance understanding of idiopathic pulmonary fibrosis .
- They developed UNAGI, a deep neural network that analyzes single-cell data to model lung scarring progression and suggest drug candidates for IPF treatment.
- UNAGI analyzed the progression of lung cells in fibrosis, revealed crucial regulatory factors, and proposed eight potential therapies, including one currently sanctioned for use in IPF.
- A separate team from China designed a biomimetic nanotherapy called BEV-SNA, achieving 17.2-fold higher vesicle production and improving drug delivery to deep lung tissues.
- These advances suggest new therapeutic strategies that could more effectively block scar formation and inflammation, potentially improving survival in this fatal lung disease.
11 Articles
11 Articles
Biomimetic nanotherapy shows promise for treating fatal lung scarring disease
Chinese scientists have developed a novel nanotherapy known as biomimetic extracellular vesicle spherical nucleic acids (BEV-SNAs), which has shown efficacy in treating idiopathic pulmonary fibrosis (IPF). The study was published in the journal Aggregate.
In Italy these diseases affect thousands of people and, at European level, are estimated to be about 400,000 cases. These are rare diseases, characterized by a progressive and irreversible development.
AI helps researchers understand lung disease and proposes treatment
The secrets of idiopathic pulmonary fibrosis (IPF) are written in its very name. Idiopathic refers to a disease of unknown cause, and the condition, which turns healthy lung tissue into fibrous scar tissue, still raises many questions.
Researchers from the University of Cadiz and the Puerta del Mar University Hospital, attached to the Institute of Biomedical Research and Innovation of Cadiz (INiBICA), have developed an innovative system to support clinical diagnosis, based on artificial intelligence, for the early detection of silicosis caused by exposure to artificial stone dust. This tool allows to identify the disease and classify its degree of severity from chest X-rays, w…
From ATS 2025: Analysis of Data Supporting PDE4 Inhibition in IPF
Panelists discuss recent phase 3 trial results of a novel oral agent for idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF), highlighting its ability to significantly reduce lung function decline and mortality—even when added to existing antifibrotic therapies—while maintaining a favorable safety and tolerability profile.
Coverage Details
Bias Distribution
- 67% of the sources are Center
To view factuality data please Upgrade to Premium
